Most clinicians assume a GLP-1 prescription only becomes a problem when a patient reacts badly to the drug. The reverse is closer to the truth. The prescription itself, the diagnosis code attached to it, and the telehealth visit that produced it are increasingly the exhibit, long before any patient is harmed.
Insurers pull the pattern first. Federal investigators pick up what the insurer flagged.
That shift changes who is exposed. The target isn’t only the pill mill operator or the offshore counterfeiter. It’s the primary care physician writing semaglutide for a patient whose chart doesn’t cleanly justify it, and the telehealth group whose intake form nudges every patient toward the same code.
The Money Made This a Target
The scrutiny follows a spending curve nobody in government is ignoring. Medicare Part D spending on GLP-1 drugs hit $27.5 billion in 2024, a five-fold jump from 2019. Coverage debates keep pushing those projections higher, with active proposals to expand Medicare coverage of GLP-1s for obesity that would add substantial spending over the next decade.
Numbers that large draw the same response every time: audits, data-mining contractors, and eventually criminal referrals. Agencies don’t need to knock on doors to start. They start with claims data.
The Obvious Fixes Don’t Actually Protect the Prescriber
When clinicians hear about GLP-1 enforcement, the reflex is to tighten a few surface habits. Add a diabetes code. Document a BMI. Move a patient to a compounded version to sidestep coverage rules.
Each of those feels protective. None of them speak to what an investigator is actually looking at.
The reason is straightforward. The enforcement lens isn’t the individual prescription. It’s the pattern across hundreds or thousands of them, sitting in a payer’s database, waiting for a query to run.
Insurers Are Now the First Investigators
Payers have moved from passive claim processors to active gatekeepers on this drug class. Prior authorization requirements have tightened. Coverage has been narrowed to specific indications. And in a development that caught many prescribers off guard, some plans have sent direct letters to high-volume GLP-1 writers warning that continued prescribing outside covered indications could become suspected fraud.
A Goodwin analysis of the shifting payer landscape documented insurers sending prescriber letters that explicitly raised the fraud-referral possibility. That is a meaningful change.
A payer letter used to be a coverage dispute. Now it can be the first page of a government file.
Part D law matters here too. Medicare cannot cover a drug prescribed solely for weight loss, but it can cover GLP-1s for diabetes and, more recently, for cardiovascular risk reduction. That legal line is exactly where a chart gets scrutinized: does the record actually support the covered indication, or does it read as weight-loss care with a diabetes label pasted on top?
The Counterfeit Problem Pulls in Legitimate Prescribers
Supply-side fraud has widened the enforcement circle. Counterfeit semaglutide has been documented in the U.S. supply chain, and state officials have pressed federal regulators to act on high-volume counterfeits arriving from overseas. When a patient is harmed by a fake, investigators trace the chain backward. The prescriber, the telehealth platform, and the fulfillment pharmacy all get pulled into the timeline, even when none of them knew the product was counterfeit.
Criminal cases are already moving. Prosecutors have brought charges tied to schemes to impersonate physicians and obtain GLP-1 medications for paying customers. Those indictments are a preview, not an outlier, and defense attorneys who handle Medicare fraud matters expect the docket to grow.
What Actually Reduces the Exposure
The prescribers and platforms who come through this era intact share a few habits. None of them are unusual. All of them are documentary.
A prescription is a clinical decision. Once it lands in a claims database, it also becomes a data point that will be compared against thousands of others. Write the record with that in mind and the exposure narrows. Ignore it, and the next letter in the mail may not come from the insurer.